NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
Related Posts
Cowen & Co. Maintains Outperform on Crown Castle, Raises Price Target to $152
Cowen & Co. analyst Gregory Williams maintains Crown Castle (NYSE:CCI) with a Outperform and raises the price target from $149 to $152.
Is The Hedge Fund Love Affair With Tech Stocks Over? Goldman Sachs Data Provides A Clue
When the COVID-19 pandemic struck in 2020, labor, education and retail went virtual with tech companies of all stripes seeing a boom.
Big tech performed especially well and hedge funds played a significant role in the purchase of those equities.